Top Injectable Manufacturer in Singapore – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 22 hours ago
- 8 min read
Last Updated: August 23, 2026
TL;DR: Singapore is one of the most demanding pharmaceutical markets in Asia and one of the most rewarding to get right. The Health Sciences Authority (HSA) regulates therapeutic products under the Health Products Act 2007 and the Health Products (Therapeutic Products) Regulations 2016, was designated a WHO-Listed Authority for its medicines regulatory system on 26 October 2023, and had already attained WHO Maturity Level 4 in January 2022. For an Indian manufacturer the decisive detail is the Verification-CECA evaluation route, which is open specifically to generic drugs manufactured in India and carries a 90-working-day evaluation turnaround. Farbe Firma Pvt Ltd manufactures sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and supports Singapore importers with PIC/S-referenced GMP evidence, CTD or ACTD dossiers and ICH-compliant stability data.
Key Takeaways
Use the route India is entitled to. HSA's Verification-CECA pathway is available to generic drugs manufactured in India that meet the standard verification criteria – approval by at least one of HSA's six reference agencies (US FDA, EMA centralised procedure, Health Canada, UK MHRA, Swissmedic, Australia TGA) within the preceding two years, unredacted assessment reports, and a product-owner declaration that all quality aspects are identical to what the reference agency approved. The evaluation turnaround is 90 working days against 120 for a standard generic verification and 240 for the abridged route, and HSA aims to issue its first communication within 14 working days of acceptance.
GMP evidence can replace an inspection. Under HSA's GMP conformity assessment framework (GUIDE-MQA-020), an overseas site that has already been inspected on-site and found compliant by at least one PIC/S member authority may submit a valid GMP certificate as documentary evidence, and no HSA on-site inspection is required if that evidence is acceptable. The alternative – a Quality System Dossier and an HSA audit – is charged at SGD 20,600 per site for an Asian country outside ASEAN, against SGD 660 for evidence evaluation. Getting the GMP evidence package right is the single largest cost and timeline lever in the whole file.
Your Singapore partner needs two licences and a pharmacist. Importing and wholesaling therapeutic products requires a Therapeutic Product Importer's Licence and a Wholesaler's Licence – bundled at SGD 1,000 and valid twelve months – and the named Responsible Person must be a registered pharmacist where the company deals in Prescription-Only Medicines. HSA audits against its Good Distribution Practice guidance (GUIDE-MQA-013, revised 15 December 2023) before issuing a dealer's licence, so a distributor's GDP posture is worth verifying before you commit to them.
Sterile injectables are judged against the revised PIC/S Annex 1. HSA is a PIC/S member and applies the current PIC/S Guide to GMP (PE 009) as its standard. The revised Annex 1 on the manufacture of sterile medicinal products came into force on 25 August 2023, with section 8.123 on lyophiliser design and the associated transfer and loading areas effective 25 August 2024. A contamination control strategy that reads as an afterthought is now visible to any assessor looking at your file.
Introduction: Why Singapore Demands a Premium Injectable Manufacturer in Singapore
Singapore is a small market that behaves like a large one. Its population of roughly 5.87 million is a fraction of the region's, yet it imported US$5.75 billion of pharmaceutical products under HS Chapter 30 in 2024 and exported US$8.41 billion – a country that both manufactures at scale and moves product onward across Asia. Supply into that market is dominated by high-cost origins: Ireland at US$1.49 billion and the United States at US$1.17 billion led the 2024 table, with Germany, France and Belgium behind them. India sat fourteenth, at US$80.6 million or about 1.4% of the total. For an Indian sterile injectable manufacturer that gap is the opportunity, not the obstacle.
It is an opportunity because Singapore has deliberately built a faster door for Indian product. Under the India-Singapore Comprehensive Economic Cooperation Agreement, HSA operates a Verification-CECA evaluation route reserved for generic drugs manufactured in India, with a 90-working-day evaluation turnaround. Nothing about that route lowers the technical bar – it still demands reference-agency approval and unredacted assessment reports – but it does mean that a manufacturer in Gujarat with a properly assembled file is competing on merit rather than on queue position. The regulator itself is credible enough to make that approval portable: HSA reached WHO Maturity Level 4 in January 2022 and was designated a WHO-Listed Authority for its medicines regulatory system on 26 October 2023.
What Sets a World-Class Injectable Manufacturer in Singapore Apart
Begin with the evaluation routes, because choosing the wrong one costs quarters rather than weeks. HSA offers three: Full, for a product not yet approved anywhere; Abridged, for a product approved by at least one drug regulatory agency; and Verification, for a product already approved by one of HSA's six reference agencies. Screening runs 50 working days for every route. After that the published evaluation turnarounds diverge sharply – a generic drug application takes 240 working days on the abridged route, 120 on verification, and 90 on Verification-CECA. Fees track the same logic: SGD 610 to screen a generic application, SGD 10,600 to evaluate a GDA-1 on the verification or Verification-CECA route, and SGD 330 a year in registration retention thereafter. Dossiers may be built in ICH CTD or ASEAN CTD format, and HSA moved to live eCTD submissions from 1 April 2026 after a test phase that opened on 30 September 2025.
Then look at what the manufacturer can put in front of HSA without improvising. The GMP conformity assessment is where an Indian site either saves months or loses them. If the site has been inspected on-site and found GMP-compliant by a PIC/S member authority, a valid GMP certificate can be submitted as documentary evidence and HSA will generally not require its own inspection, at a fee of SGD 660 per site. If it has not, the fallback is a Quality System Dossier under GUIDE-MQA-019 and an on-site HSA audit charged at SGD 20,600 for a site in an Asian country outside ASEAN. The same discipline applies one layer back: for an overseas drug substance manufacturer, HSA expects a PIC/S authority's GMP certificate that names the drug substance, and where it does not, a Written Confirmation from the issuing authority. From 16 January 2026 HSA also runs a defined procedure for inspecting overseas drug substance sites that lack GMP evidence, requiring an expression of interest at least three months ahead.
Quality Systems Behind Every Sterile Injectable
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is designed in rather than tested in: terminal sterilisation or aseptic processing selected on the product's own merits, media fill validation, routine environmental and personnel monitoring, container closure integrity testing, and a documented contamination control strategy of the kind the revised PIC/S Annex 1 now expects to see articulated rather than assumed. Release testing runs on HPLC and GC for assay and impurities, LAL for bacterial endotoxins, Karl Fischer for water content where the presentation calls for it, and full compendial sterility testing.
Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B. Singapore sits in climatic Zone IVb, so shelf life is defended on 30°C/75% RH long-term data rather than on a temperate dataset that will not survive scrutiny – and the same data travels intact to the ASEAN neighbours a Singapore distributor is often serving in parallel. Documentation is assembled in CTD or ACTD structure with the module-level detail HSA's application checklists call for, and where a verification route is used we prepare the unredacted assessment reports and the product-owner quality-identity declaration as part of the package rather than as a late deficiency response.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Singapore for Global Buyers
Singapore rewards suppliers who understand that registration is only half the job. Once a product is registered, the commercial routes run through the public healthcare system and the private sector in parallel. ALPS Pte Ltd, the government-linked national integrated supply chain and procurement agency for the public healthcare sector, runs national and pharmaceutical sourcing events and publishes its own supplier code of conduct, process guidelines and contract templates. Subsidy sits alongside it: the Standard Drug List covers common conditions and the Medication Assistance Fund covers high-cost medicines assessed as clinically proven and cost-effective, with Singapore citizens subsidised up to 75% at public healthcare institutions, and the Agency for Care Effectiveness conducting the health technology assessment that feeds the List of Subsidised Drugs. A generic injectable that is cheap but cannot document its equivalence to a reference-agency-approved product does not get far in that environment.
Regulatory currency matters just as much, because HSA keeps moving. Four changes took effect on 16 January 2026 alone: a new submission pathway for Standard Essential Medicines via a generic drug application, aimed at unregistered medicines with long local clinical use and well-established efficacy and safety in recognised references and requiring an expression of interest at least three months before submission; removal of the previous limit of three concurrent major variation applications in PRISM; the overseas drug substance inspection procedure noted above; and mandatory conflict-of-interest declarations from company-engaged expert clinicians. A manufacturing partner who is not tracking those changes will hand your Singapore agent a file that was correct last year.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which is the right shape for a market served through licensed importers and wholesalers with tender-driven and private-sector demand running side by side. We support English-language artwork and package inserts, flexible batch sizes so a distributor is not forced to buy a tender-scale quantity to serve a private channel, dossier compilation in CTD or ACTD with eCTD-ready structure, and the GMP evidence, certificates of analysis and stability packages your Responsible Person will be asked for. Contract development and manufacturing arrangements, own-label supply and technology transfer are all available, with the same quality system behind each.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates injectable medicines in Singapore?
The Health Sciences Authority (HSA), through its Health Products Regulation Group. Therapeutic products are regulated under the Health Products Act 2007 and the Health Products (Therapeutic Products) Regulations 2016. HSA attained WHO Maturity Level 4 in January 2022 and was designated a WHO-Listed Authority for its medicines regulatory system on 26 October 2023, which is why a Singapore approval carries weight well beyond Singapore.
Is there a faster registration route for medicines made in India?
Yes. HSA operates a Verification-CECA evaluation route under the India-Singapore Comprehensive Economic Cooperation Agreement, available to generic drugs manufactured in India that meet the standard verification criteria. The published evaluation turnaround is 90 working days, against 120 working days for standard generic verification and 240 for the abridged route, with HSA aiming to issue its first communication within 14 working days of acceptance. Screening takes 50 working days on every route.
Will HSA inspect an Indian manufacturing site before approving a product?
Not necessarily. Under HSA's GMP conformity assessment framework (GUIDE-MQA-020), a site already inspected on-site and found GMP-compliant by at least one PIC/S member authority may submit a valid GMP certificate as documentary evidence, and HSA will generally not require its own inspection where that evidence is acceptable – though it reserves the right to inspect. Evidence evaluation is charged at SGD 660 per site; the on-site audit alternative is SGD 20,600 for a site in an Asian country outside ASEAN, and requires a Quality System Dossier.
What licences does my Singapore importer or distributor need?
A Therapeutic Product Importer's Licence and a Therapeutic Product Wholesaler's Licence, which HSA bundles at SGD 1,000 for a twelve-month term. The licence names a Responsible Person, who must be a registered pharmacist where the company handles Pharmacy-only or Prescription-Only Medicines for local use. HSA audits applicants against its Good Distribution Practice guidance (GUIDE-MQA-013, revised 15 December 2023) before issuing the licence, and compliance with that guidance is mandatory thereafter.
What makes Farbe Firma a suitable injectable manufacturer for the Singapore market?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. We prepare CTD or ACTD dossiers with eCTD-ready structure, generate ICH Q1A(R2) and Q1B stability data on Zone IVb conditions appropriate to Singapore and its ASEAN neighbours, supply the GMP evidence and analytical documentation an HSA file requires, and support English-language artwork and package inserts. Contact director@farbefirma.org to discuss a specific molecule or tender.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments